

# Drug & Market Development

Linking R&D and Marketing in the Pharmaceutical and Biotechnology Industries

## Therapeutic & Market Updates

### Cardiovascular & Blood

#### 391 Recent Advances in the Treatment of Hematological Diseases

This article discusses the latest developments concerning the treatment of a range of malignant and non-malignant hematologic diseases. The studies detailed cover a variety of chemotherapeutic, biological, biotechnological, and radiological approaches that offer significant activity, improved progression-free and overall survival time for hematologic malignancies, and preventative or therapeutic modalities for numerous non-malignant disorders.

### Nervous System

#### 397 Glutamate-Targeted CNS Drugs—Closing in on a Holy Grail?

Successful glutamatergic manipulation could mean paradigm shifts in the treatment of neurological and psychiatric diseases/disorders and concomitant huge market potentials. Drug development targeting ionotropic glutamate receptors has advanced from earliest efforts with competitive NMDA antagonists to targeting all three receptor families and family sub-units. This article details the latest in glutamate-targeted drug development, providing thorough coverage of pharmacologic approaches for manipulating the glutamate system and current status of glutamate-targeted preclinical and clinical candidates.

## Strategic Issues

#### 402 RNAi (Part II)—Emerging Business Opportunities

As a follow-on to the Drug & Market Development (2004;15[1]: 377-379) article "RNAi (Part I)—The Technology and Its Applications," this article presents an analysis of the emerging business opportunities in the RNAi space and the business and commercialization aspects of RNAi; as well, segments where the bulk of the commercial opportunity exists are explored.

## Technology Trends

#### 406 Updates in the Development of Vaccines

Vaccines are currently the focus of some of the most active,

cutting-edge research in the pharmacotherapeutic field. In addition to discussing new vaccine developments to counter bioterrorism and new infectious diseases, this article discusses strategies for vaccine development and provides an update on the status of select vaccine clinical candidates.

#### 408 Ion Channel Drug Discovery: Expanding Market Opportunity

As follow-on to the Drug & Market Development (2003;14[12]: 344-347) article "Emerging Trends in the Top-Tier Pharmaceutical Targets That Offer Growth Opportunity," this article presents a detailed market analysis of the ion channels space. The article focuses on mapping the business and market landscape for ion channel interrogation and screening in order to identify niche business opportunities.

## International Developments

#### 413 Country Focus—The U.K.: R&D Strengths and Market Opportunities

The U.K. is the dominant player in the European biotechnology sector, with 43% of total market capitalization (\$12.0 billion [€9.4 billion]) and 37% (\$3.7 billion [€2.9 billion]) of revenue. U.K. companies account for 48% of products in clinical trials by European public biotech companies and 53% of new biotechnology drugs in late-stage clinical trials. This article reviews the current state of the U.K. pharmaceutical and biotechnology markets and addresses future challenges and opportunities.

## Erratum

#### 418 Post-Genomic Biomarkers—Commercial Implications

This erratum provides a correction to the January 2004 (Vol.15, No.1) issue.

## Regular Features

#### 386 Conference Calendar

#### 387 Late-Stage Clinical Developments

### What's Coming up in the March Issue of Drug & Market Development?

- Nuclear Receptor-Targeted Drugs for Inflammatory Diseases
- Overview of and Business Opportunities in the Apoptosis Space
- Latest Drug Developments for Pancreatic Cancer
- Emerging Therapeutics for the Treatment of Parkinson's Disease
- The Threat of Generic Biologics
- Early-Stage Biotech Partnering and Dealmaking—Drivers, Deals, and Direction for 2004